Literature DB >> 12943986

Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression.

William R Harrington1, Shubin Sheng, Daniel H Barnett, Larry N Petz, John A Katzenellenbogen, Benita S Katzenellenbogen.   

Abstract

Estrogens exert their regulatory transcriptional effects, which can be stimulatory or repressive, at diverse gene sites via two estrogen receptors, ERalpha and ERbeta. Since these two ERs have different tissue distributions, ligands that have the capacity to selectively activate or inhibit these two ERs would be useful in elucidating the biology of these two receptors and might assist in the development of estrogen pharmaceuticals with improved tissue selectivity. We have developed several ligands that showed ERalpha or ERbeta selectivity at promoter-gene sites containing consensus estrogen response elements (EREs): ERalpha-selective agonist (propyl-pyrazole-triol (PPT)), ERalpha-selective antagonist (methyl-piperidino-pyrazole (MPP)), ERbeta-potency selective agonist (diarylpropionitrile (DPN)) and ERbeta-selective antagonist/ERalpha-agonist (R,R-tetrahydrochrysene (R,R-THC)). In this study, we have examined the activity of these compounds at a range of gene sites where ER stimulates gene expression through non-consensus EREs (complement C3), or multiple half-EREs (NHE-RF/EBP50), or by tethering to DNA via other proteins (TGF beta3 and progesterone receptor A/AP-1), and at gene sites where ER represses gene transcription (interleukin-6). At all of these genes, PPT showed full stimulation through ERalpha while displaying no agonism through ERbeta. MPP antagonized estradiol actions on gene transactivation and transrepression through ERalpha, with little or no effect on transcription mediated through ERbeta. DPN displayed subtype-selective agonism, being ca. 30-fold more potent through ERbeta. R,R-THC was a complete antagonist through ERbeta and displayed agonism through ERalpha, the level of which was promoter dependent. Because these ligands maintain their agonist or antagonist character and ER subtype-selectivity at gene sites of diverse nature, where estradiol is either stimulatory or inhibitory, these compounds should prove useful in elucidating the biological functions of ERalpha and ERbeta.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12943986     DOI: 10.1016/s0303-7207(03)00255-7

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  115 in total

1.  Estrogen receptor-mediated enhancement of venous relaxation in female rat: implications in sex-related differences in varicose veins.

Authors:  Joseph D Raffetto; Xiaoying Qiao; Katie G Beauregard; Raouf A Khalil
Journal:  J Vasc Surg       Date:  2010-04       Impact factor: 4.268

2.  17β-oestradiol acts as a negative modulator of insulin-induced lactotroph cell proliferation through oestrogen receptor α, via nitric oxide/guanylyl cyclase/cGMP.

Authors:  S Gutiérrez; J P Petiti; L d V Sosa; L Fozzatti; A L De Paul; A M Masini-Repiso; A I Torres
Journal:  Cell Prolif       Date:  2010-10       Impact factor: 6.831

3.  ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.

Authors:  V Duong; A Licznar; R Margueron; N Boulle; M Busson; M Lacroix; B S Katzenellenbogen; V Cavaillès; G Lazennec
Journal:  Oncogene       Date:  2006-03-16       Impact factor: 9.867

4.  Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice.

Authors:  Cedric Le May; Khoi Chu; Min Hu; Christina S Ortega; Evan R Simpson; Kenneth S Korach; Ming-Jer Tsai; Franck Mauvais-Jarvis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

5.  Ginsenoside Rb1 inhibits tube-like structure formation of endothelial cells by regulating pigment epithelium-derived factor through the oestrogen beta receptor.

Authors:  K W Leung; L W T Cheung; Y L Pon; R N S Wong; N K Mak; T-P D Fan; S C L Au; J Tombran-Tink; A S T Wong
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

6.  Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors.

Authors:  Ratna K Vadlamudi; Seetharaman Balasenthil; Russell R Broaddus; Jan-Ake Gustafsson; Rakesh Kumar
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

7.  A human estrogen receptor (ER)alpha mutation with differential responsiveness to nonsteroidal ligands: novel approaches for studying mechanism of ER action.

Authors:  Ramasamy Paulmurugan; Anobel Tamrazi; John A Katzenellenbogen; Benita S Katzenellenbogen; Sanjiv S Gambhir
Journal:  Mol Endocrinol       Date:  2008-05-01

8.  Subtype-specific estrogen receptor-mediated vasodilator activity in the cephalic, thoracic, and abdominal vasculature of female rat.

Authors:  Ossama M Reslan; Zongzhi Yin; Graciliano R A do Nascimento; Raouf A Khalil
Journal:  J Cardiovasc Pharmacol       Date:  2013-07       Impact factor: 3.105

9.  Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice.

Authors:  Seema Tiwari-Woodruff; Rhonda R Voskuhl
Journal:  J Neurol Sci       Date:  2009-05-13       Impact factor: 3.181

Review 10.  Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels.

Authors:  Dia A Smiley; Raouf A Khalil
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.